We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+150.31%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$412M
Cap. Flow
+$25.7M
Cap. Flow %
2.41%
Top 10 Hldgs %
48.66%
Holding
270
New
60
Increased
70
Reduced
50
Closed
53

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$27.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.5M
3
ROIV icon
Roivant Sciences
ROIV
+$17.4M
4
ETNB
89bio
ETNB
+$12.6M
5
JANX icon
Janux Therapeutics
JANX
+$7.04M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$105M
2
PRTA icon
Prothena Corp
PRTA
+$14.6M
3
CGON icon
CG Oncology
CGON
+$7.97M
4
SAGE
Sage Therapeutics
SAGE
+$6.58M
5
VERV
Verve Therapeutics
VERV
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.19%
2 Financials 1.65%
3 Communication Services 0.09%
4 Consumer Discretionary 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSHA icon
26
Taysha Gene Therapies
TSHA
$1.86B
$9.27M 0.87%
2,835,680
-174,190
-6% -$493K
REGN icon
27
Regeneron Pharmaceuticals
REGN
$79.1B
$8.83M 0.83%
15,700
+12,339
+367% +$6.98M
IONS icon
28
Ionis Pharmaceuticals
IONS
$9.01B
$8.75M 0.82%
133,818
-14,643
-10% -$715K
JANX icon
29
Janux Therapeutics
JANX
$976M
$8.58M 0.81%
351,032
+288,944
+465% +$7.04M
IKT icon
30
Inhibikase Therapeutics
IKT
$377M
$8.5M 0.8%
5,247,603
+125,498
+2% +$217K
IVVD icon
31
Invivyd
IVVD
$178M
$8.11M 0.76%
+7,370,987
New +$6.54M
MTSR
32
DELISTED
Metsera Inc
MTSR
$7.98M 0.75%
+152,521
New +$5.63M
EQ icon
33
Equillium
EQ
$138M
$7.95M 0.75%
+5,559,988
New +$5.88M
PCSC
34
DELISTED
Perceptive Capital Solutions
PCSC
$7.92M 0.74%
750,000
– –
QURE icon
35
uniQure
QURE
$3.07B
$7.78M 0.73%
+133,316
New +$2.42M
PCVX icon
36
Vaxcyte
PCVX
$8.07B
$7.67M 0.72%
213,064
+115,032
+117% +$3.81M
RZLT icon
37
Rezolute
RZLT
$451M
$7.67M 0.72%
815,975
-173,322
-18% -$1.15M
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.22B
$7.59M 0.71%
189,098
-70,405
-27% -$2.48M
ASND icon
39
Ascendis Pharma A/S
ASND
$16B
$7.23M 0.68%
36,345
+34,943
+2,492% +$6.52M
SVRA icon
40
Savara
SVRA
$1.13B
$7.1M 0.67%
1,988,288
-1,612,382
-45% -$4.77M
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.68B
$6.74M 0.63%
349,807
+139,494
+66% +$2.49M
RVMD icon
42
Revolution Medicines
RVMD
$41.9B
$6.5M 0.61%
139,136
+5,000
+4% +$196K
AAM
43
DELISTED
AA Mission Acquisition Corp
AAM
$6.08M 0.57%
578,359
– –
BBOT
44
BridgeBio Oncology
BBOT
$718M
$5.8M 0.55%
501,228
+58,613
+13% +$611K
VRNA
45
DELISTED
Verona Pharma
VRNA
$5.49M 0.52%
51,450
+23,000
+81% +$2.4M
OACCU
46
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$199M
$5.48M 0.51%
516,482
– –
TEVA icon
47
Teva Pharmaceuticals
TEVA
$40.5B
$5.41M 0.51%
267,816
-78,062
-23% -$1.37M
RYTM icon
48
Rhythm Pharmaceuticals
RYTM
$7.59B
$5.01M 0.47%
49,571
+4,181
+9% +$388K
ATAI icon
49
AtaiBeckley Inc
ATAI
$2.67B
$4.83M 0.45%
+913,242
New +$3.71M
UTHR icon
50
United Therapeutics
UTHR
$22B
$4.7M 0.44%
+11,200
New +$3.77M
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

ADAR1 Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, ADAR1 Capital Management held 270 positions worth $1.06B, up 63% from $652M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

ADAR1 Capital Management's Q3 2025 filing shows 60 new, 70 increased, 50 reduced and 53 closed positions. Its largest new stake was Invivyd: 7,370,987 shares worth $8.11M. The largest sale was Abivax, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

  • ADAR1 Capital Management's largest Q3 2025 buy was Invivyd: 7,370,987 shares worth $8.11M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2025, an estimated $27.6M increase.
  • ADAR1 Capital Management's biggest Q3 2025 reduction was Abivax, cutting an estimated $105M.
  • ADAR1 Capital Management fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.58M.
  • ADAR1 Capital Management's ten largest holdings make up 49% of its $1.06B portfolio in Q3 2025.
  • ADAR1 Capital Management opened 60 new positions and closed 53 in Q3 2025.
  • ADAR1 Capital Management's portfolio value rose 63% quarter-over-quarter to $1.06B.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.